Literature DB >> 6838434

Increased low density lipoprotein production associated with obesity.

Y A Kesaniemi, S M Grundy.   

Abstract

Turnover rates of the apolipoprotein of low density lipoproteins (apoLDL) and cholesterol balance were determined in six obese men and six control men. The two groups were of similar age and matched for apoLDL concentrations. Levels of plasma total cholesterol in obese patients (209 +/- 14 SEM mg/dl) were similar to controls (225 +/- 17 mg/dl). LDL-cholesterol was numerically but not statistically lower in obese subjects (111 +/- 18 mg/dl) compared to controls (145 +/- 13 mg/dl). Synthetic rates of apoLDL in contrast were higher in obese patients (1450 mg/day) than in controls (934 mg/day) (p less than 0.002). Three factors could explain the similar concentrations of LDL-cholesterol in obese and control subjects, despite overproduction of apoLDL in the obese. First, LDL was diluted into a larger plasma pool in obese patients; second, fractional catabolic rates of apoLDL were somewhat greater in obese men than in controls; and third, obese patients had higher ratios of protein-to-cholesterol in LDL. The production of apoLDL for all patients was not correlated with total body synthesis of cholesterol. The major finding of this study was that obese patients have increased turnover of apoLDL, not necessarily reflected by high concentrations of LDL-cholesterol. This high turnover rate itself may raise the risk for coronary heart disease in obese patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838434     DOI: 10.1161/01.atv.3.2.170

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  10 in total

1.  Characterization of high density lipoprotein binding to human adipocyte plasma membranes.

Authors:  B S Fong; P O Rodrigues; A M Salter; B P Yip; J P Despres; A Angel; R E Gregg
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

2.  In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.

Authors:  G L Vega; S M Grundy
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

Review 3.  The evaluation and treatment of hypercholesterolemia in primary care practice.

Authors:  W L Peters; A H Goroll
Journal:  J Gen Intern Med       Date:  1986 May-Jun       Impact factor: 5.128

4.  An analysis of genotype effects and their interactions by using the apolipoprotein E polymorphism and longitudinal data.

Authors:  R Gueguen; S Visvikis; J Steinmetz; G Siest; E Boerwinkle
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

5.  Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations.

Authors:  E Boerwinkle; S Brown; A R Sharrett; G Heiss; W Patsch
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

6.  Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.

Authors:  Y A Kesäniemi; W F Beltz; S M Grundy
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

Review 7.  Benefits of aerobic conditioning and diet for overweight adults.

Authors:  R D Hagan
Journal:  Sports Med       Date:  1988-03       Impact factor: 11.136

8.  Influence of obesity on the metabolism of apolipoprotein B in humans.

Authors:  G Egusa; W F Beltz; S M Grundy; B V Howard
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Coronary risk factor prevalence in a high incidence area: results from the Belfast MONICA Project.

Authors:  A E Evans; M M Kerr; E E McCrum; D McMaster; L K McCartney; M Mallaghan; C C Patterson
Journal:  Ulster Med J       Date:  1989-04

10.  Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways.

Authors:  Xiaoquan Rao; Shi Zhao; Zachary Braunstein; Hong Mao; Michael Razavi; Lihua Duan; Yingying Wei; Amelia C Toomey; Sanjay Rajagopalan; Jixin Zhong
Journal:  EBioMedicine       Date:  2019-02-07       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.